STTCOMP BOT FA LONG Share Price: 9.3c Cash On Hand: $24m Market Cap: $90m
Biopharmaceutical clinical testing phase company based in Australia and US, currently testing the antimicrobial properties of synthetic cannabidiol.
Current Phase 2A clinical test with 60 healthy patients being undertaken in Perth with a readout expected in 4Q CY2020. The share price should continue to move up as interest in the test expands.
BTX 1801 is already known to be safe for humans and efficacious ex vivo in killing MRSA (Golden Staf) on human skin explants. The mechanism is well understood to degrade the bacteria's membrane causing cell death.
The trade I am suggesting is playing the increasing investor interest for a 25% - 50% gain and then reducing position based on your confidence that the clinical trial will be successful. A good readout would rerate BOT significantly and we have examples in the recent past from PAR and OPT of multi bags on Phase 2A success.
BTX 1801 is already known to the FDA who conferred Qualified Infections Disease Product status, a five year extra marketing exclusivity.
Caution: high risk, high reward so position accordingly.
